NUMARES
8.6.2020 14:02:12 CEST | Business Wire | Press release
numares appoints Winton Gibbons, as new president of its US subsidiary, numares Group Corp., effective of June 1st , 2020. Mr. Gibbons will further strengthen commercialization of numares’ products, and help expand the existing network of collaboration partners and investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005045/en/
Winton Gibbons brings to numares almost 30 years of experience related to life science businesses, particularly diagnostics. He has extensive experience in business development, strategy, and new product innovation, as well as in financial services and management consulting. As head of numares Group Corp., he will be responsible for further commercializing the company’s in-vitro diagnostic products, growing collaborations, and expanding investors.
“We are very excited to have Winton Gibbons joining us,” says Dr. Volker Pfahlert, Chief Executive Officer of numares . “His large pool of experiences in the IVD sector will help us unlock even more possibilities in the US market to support numares in its North American expansion. His in-depth knowledge and relevant experience in developing early- and mid-stage in-vitro diagnostic and life science firms will be invaluable to numares .”
German diagnostics company numares has its main market in the United States, providing a unique diagnostics approach – the “numares model,” a distinctive nuclear magnetic resonance (NMR) technology to identify metabolite constellations for diagnostic purposes. Just recently, numares and US-based Mayo Clinic Laboratories announced their collaboration to develop new diagnostic tests.
"I am excited to lead numares in the US. In a relatively short time, numares has built a strong track record as a provider of a unique diagnostic approach, and is now focused on some very exciting new products,” commented Mr. Gibbons. “I look forward to building the market for the company’s innovative product pipeline, some of which should be filed with the FDA by yearend.”
In recent years, Mr. Gibbons has consulted for innovative clinical diagnostic and life science companies, focusing on market assessment, business development, and strategy. Prior to that he was Senior Vice President of corporate development for Agena Bioscience, following his position as CEO and President of Siloam Biosciences, where he evaluated and implemented strategic options for the company, secured bridge financing, and managed investment banking relationships. This followed his senior management roles in business development for Nanosphere, and strategic marketing for Biosite. Leading up to this, Mr. Gibbons spent 8 years at William Blair, a global investment banking & wealth management firm, where he was a Principal, sell-side Stock Analyst, and Healthcare Equity Research Group Head. Early in his career, he was a consultant and manager for McKinsey & Company, after which he worked for Boehringer Mannheim and Merck. He has also served on several industry and academic advisory boards. Mr. Gibbons holds an MBA from the University of Chicago, and a degree in chemistry from Duke University.
About numares
numares , based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolic data to develop advanced analytical tests for high-throughput use in clinical diagnostics and life science research. The company’s AXINON® system employs nuclear magnetic resonance (NMR) spectroscopy to create a spectrum standardized by Magnetic Group SignalingTM (MGS® ) to evaluate metabolite constellations. MGS® is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests are an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology. More information: https://www.numares.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom